Jaguar Health

Historical price data

Jaguar Health is a commercial-stage biopharmaceutical company with a mission to develop and commercialize novel, plant-based prescription medicines for gastrointestinal conditions. Its core asset is Mytesi (crofelemer), the first and only FDA-approved anti-secretory agent for HIV/AIDS-related diarrhea, derived sustainably from the Croton lechleri tree. The company is leveraging its expertise in botanical drug development to expand crofelemer's indications into cancer therapy-related diarrhea and other areas of significant unmet need, while also exploring its potential in veterinary medicine through its subsidiary, Napo Therapeutics.

Development of novel, plant-based, anti-secretory therapeutics derived from sustainable botanical sources, with a core focus on crofelemer, a first-in-class inhibitor of intestinal chloride channels.

Faces competition from over-the-counter loperamide and injectable somatostatin analogs in CTD. Key differentiation is crofelemer's unique, locally-acting, anti-secretory mechanism that relieves diarrhea without causing constipation, making it suitable for chronic use in cancer and HIV patients.